Profile data is unavailable for this security.
About the company
Eliem Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. Its clinical-stage program, ETX-155, is an investigational, oral, neuroactive steroid NCE that is designed to act as a positive allosteric modulator (PAM) of the GABAA receptor (GABAAR). The GABAA PAM neuroactive steroid class has been clinically validated in depression and epilepsy, with Sage Therapeutics receiving approval from the United States. ETX-155 for use in multiple disorders of high unmet need, including major depressive disorder (MDD) and focal onset seizures (FOS). It has designed several lead series based on novel chemistry and selected a lead clinical candidate, ETX-123. The ETX-123 molecule displays potent activation of Kv7.2/3 in vitro with an approximately 0.7 nM EC50.
- Revenue in USD (TTM)0.00
- Net income in USD-35.12m
- Incorporated2018
- Employees9.00
- LocationEliem Therapeutics Inc2801 CENTERVILLE ROAD 1ST FLOORPMB #117WILMINGTON 19808United StatesUSA
- Phone+1 (425) 276-2300
- Fax+1 (302) 636-5454
- Websitehttps://eliemtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 220.75m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0149 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| AVITA Medical Inc | 50.14m | -35.38m | 224.97m | 207.00 | -- | 4.57 | -- | 4.49 | -1.40 | -1.40 | 1.98 | 1.91 | 0.4778 | 1.96 | 8.48 | 242,236.70 | -33.71 | -- | -38.04 | -- | 84.93 | -- | -70.56 | -- | 7.46 | -35.40 | 0.448 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -42.49m | 227.02m | 32.00 | -- | 1.42 | -- | -- | -0.3343 | -0.3343 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -23.84 | -41.75 | -25.56 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Metagenomi Inc | 44.76m | -68.26m | 231.20m | 236.00 | -- | -- | -- | 5.17 | -1.82 | -1.82 | 1.19 | 5.73 | -- | -- | -- | 189,644.10 | -- | -- | -- | -- | -- | -- | -152.50 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| G1 Therapeutics Inc | 82.51m | -47.97m | 232.23m | 100.00 | -- | 6.52 | -- | 2.81 | -0.953 | -0.953 | 1.53 | 0.6815 | 0.5332 | 0.5028 | 6.94 | 825,110.00 | -31.00 | -47.06 | -39.28 | -52.64 | 91.28 | -- | -58.13 | -268.59 | 3.45 | -5.22 | 0.593 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Eliem Therapeutics Inc | 0.00 | -35.12m | 235.28m | 9.00 | -- | 2.16 | -- | -- | -1.31 | -1.31 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -28.61 | -- | -29.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Codexis Inc | 70.14m | -76.24m | 235.66m | 174.00 | -- | 2.70 | -- | 3.36 | -1.12 | -1.12 | 1.03 | 1.24 | 0.3625 | 5.43 | 2.31 | 403,120.70 | -39.41 | -17.13 | -50.48 | -20.23 | 81.74 | 77.29 | -108.69 | -37.04 | 2.53 | -- | 0.00 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Puma Biotechnology Inc | 235.64m | 21.59m | 239.11m | 185.00 | 10.99 | 4.42 | 7.22 | 1.01 | 0.4515 | 0.4515 | 4.96 | 1.12 | 1.04 | 10.80 | 5.23 | 1,273,714.00 | 9.54 | -12.21 | 15.66 | -20.53 | 73.40 | 78.78 | 9.16 | -11.79 | 1.50 | 3.10 | 0.6509 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| Veru Inc | 15.93m | -64.59m | 240.07m | 189.00 | -- | 4.65 | -- | 15.07 | -0.758 | -0.758 | 0.177 | 0.3525 | 0.1728 | 1.01 | 5.10 | 84,285.19 | -70.07 | -42.91 | -101.20 | -54.41 | 50.31 | 72.41 | -405.44 | -104.96 | 2.79 | -- | 0.1584 | -- | -58.59 | 0.5394 | -10.84 | -- | 67.39 | -- |
| AC Immune SA | 16.26m | -59.56m | 242.04m | 133.00 | -- | 1.37 | -- | 14.89 | -0.7049 | -0.7049 | 0.1914 | 1.78 | 0.0803 | -- | 1.92 | 122,224.80 | -29.41 | -18.25 | -31.56 | -19.52 | -- | -- | -366.41 | -148.29 | -- | -89.52 | 0.0213 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| XBiotech Inc | 0.00 | -24.56m | 244.22m | 82.00 | -- | 1.12 | -- | -- | -0.8068 | -0.8068 | 0.00 | 7.19 | 0.00 | -- | -- | 0.00 | -10.39 | 31.88 | -10.62 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.00 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Coherus Biosciences Inc | 257.24m | -237.89m | 246.29m | 306.00 | -- | -- | -- | 0.9574 | -2.56 | -2.56 | 2.74 | -1.72 | 0.4633 | 3.14 | 1.39 | 840,666.70 | -42.85 | -21.43 | -74.34 | -29.32 | 38.19 | 79.01 | -92.48 | -36.56 | 1.24 | -4.77 | 1.69 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Fennec Pharmaceuticals Inc | 21.25m | -16.05m | 246.34m | 36.00 | -- | -- | -- | 11.59 | -0.6042 | -0.6042 | 0.7994 | -0.43 | 0.79 | 0.9217 | 4.10 | -- | -59.64 | -73.43 | -77.06 | -84.32 | 94.08 | -- | -75.50 | -383.28 | 3.27 | -3.90 | 1.63 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Candel Therapeutics Inc | 0.00 | -37.94m | 247.40m | 42.00 | -- | 19.24 | -- | -- | -1.31 | -1.31 | 0.00 | 0.4381 | 0.00 | -- | -- | 0.00 | -63.82 | -- | -76.57 | -- | -- | -- | -- | -- | -- | -73.91 | 0.6254 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Century Therapeutics Inc | 2.24m | -136.67m | 248.54m | 152.00 | -- | 0.9797 | -- | 111.20 | -2.30 | -2.30 | 0.0377 | 3.06 | 0.0053 | -- | -- | 14,703.95 | -32.26 | -- | -34.19 | -- | -- | -- | -6,115.12 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Eliem Therapeutics Inc's reporting currency: US Dollar USD
60.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 10 Apr 2024 | 13.15m | 47.70% |
| BML Capital Management LLCas of 31 Mar 2024 | 2.19m | 7.96% |
| Driehaus Capital Management LLCas of 31 Dec 2023 | 811.68k | 2.94% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 310.49k | 1.13% |
| Atom Investors LPas of 31 Dec 2023 | 78.28k | 0.28% |
| Geode Capital Management LLCas of 31 Dec 2023 | 66.63k | 0.24% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 55.22k | 0.20% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 30.01k | 0.11% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 29.95k | 0.11% |
| Tudor Investment Corp.as of 31 Dec 2023 | 29.49k | 0.11% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
